title: An Important Step Forward for Biosimilars in Cancer Treatment.
authors.affiliation: Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York2Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Schleicher
authors.affiliation: Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York3Department of Medicine, Weill Cornell Medical College, New York, New York.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Seidman
mesh_terms: D000328:Adult; D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D057194:Intention to Treat Analysis; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D000068878:Trastuzumab / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D059451:Biosimilar Pharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human